Navigating Bispecific Antibodies for Multiple Myeloma: Best Practices and Clinical Implementation

Meeting Objectives:

• • Identify unmet needs and recent trends in the management of patients with relapsed/refractory multiple myeloma (R/R MM) receiving bispecific antibody therapies.
  • Using real-world patient cases, analyze recent guideline updates and new treatment data from clinical trials to make informed, personalized recommendations for patients receiving bispecific antibody therapy for relapsed/refractory multiple myeloma (R/R MM).
  • Discuss the integral role of pharmacists in the implementation and management of bispecific antibody therapies for R/R MM, including therapy sequencing, toxicity monitoring and management, and operationalizing bispecific therapy use.